CMS-HCC Risk Adjustment · V28 Model · Payment Year 2026 78 Codes

HCC 17: Cancer Metastatic to Lung, Liver, Brain, and Other Organs; Acute Myeloid Leukemia Except Promyelocytic ICD-10-CM

CMS-HCC Category 17 (Cancer Metastatic to Lung, Liver, Brain, and Other Organs; Acute Myeloid Leukemia Except Promyelocytic) is a payment HCC in the V28 Medicare Advantage risk adjustment model. For payment year 2026 it adds a risk adjustment factor between 1.952 and 4.235 to a beneficiary's RAF score depending on the payment segment (4.209 for a community, non-dual, aged enrollee). 78 ICD-10-CM diagnosis codes map to HCC 17. It sits at the top of its hierarchy: no other condition category supersedes it.

✓ Built from the official CMS PY 2026 risk adjustment filesV28 pays 100% of MA risk scores from PY 2026
+4.209
RAF, Community Non-Dual Aged
78
ICD-10-CM Codes
Top
Of Its Hierarchy
PY 2026
Dataset
CMS-HCC V28

RAF Weight by Payment Segment 7 segments

Payment SegmentRelative Factor
Community, non-dual, aged4.209
Community, partial-benefit dual, aged3.946
Community, full-benefit dual, aged3.896
Community, non-dual, disabled3.995
Community, partial-benefit dual, disabled4.103
Community, full-benefit dual, disabled4.235
Institutional1.952

A beneficiary is scored in exactly one segment, set by Medicaid (dual) status, aged or disabled entitlement, and residence. Factors are relative weights, not dollar amounts; new-enrollee segments score on demographics only. HCC 17 in turn supersedes HCC 18 (Cancer Metastatic to Bone, Other and Unspecified Metastatic Cancer; Acute Leukemia Except Myeloid), HCC 19 (Myelodysplastic Syndromes, Multiple Myeloma, and Other Cancers), HCC 20 (Lung and Other Severe Cancers), HCC 21 (Lymphoma and Other Cancers), HCC 22 (Bladder, Colorectal, and Other Cancers), and HCC 23 (Prostate, Breast, and Other Cancers and Tumors).

ICD-10-CM

ICD-10-CM Codes That Map to HCC 17 78 codes

78 of 78 shown
  • C77.1 Secondary and unspecified malignant neoplasm of intrathoracic lymph nodes from V24 HCC 8
  • C77.8 Secondary and unspecified malignant neoplasm of lymph nodes of multiple regions from V24 HCC 8
  • C78.00 Secondary malignant neoplasm of unspecified lung from V24 HCC 8
  • C78.01 Secondary malignant neoplasm of right lung from V24 HCC 8
  • C78.02 Secondary malignant neoplasm of left lung from V24 HCC 8
  • C78.1 Secondary malignant neoplasm of mediastinum from V24 HCC 8
  • C78.2 Secondary malignant neoplasm of pleura from V24 HCC 8
  • C78.30 Secondary malignant neoplasm of unspecified respiratory organ from V24 HCC 8
  • C78.39 Secondary malignant neoplasm of other respiratory organs from V24 HCC 8
  • C78.4 Secondary malignant neoplasm of small intestine from V24 HCC 8
  • C78.5 Secondary malignant neoplasm of large intestine and rectum from V24 HCC 8
  • C78.6 Secondary malignant neoplasm of retroperitoneum and peritoneum from V24 HCC 8
  • C78.7 Secondary malignant neoplasm of liver and intrahepatic bile duct from V24 HCC 8
  • C78.80 Secondary malignant neoplasm of unspecified digestive organ from V24 HCC 8
  • C78.89 Secondary malignant neoplasm of other digestive organs from V24 HCC 8
  • C79.00 Secondary malignant neoplasm of unspecified kidney and renal pelvis from V24 HCC 8
  • C79.01 Secondary malignant neoplasm of right kidney and renal pelvis from V24 HCC 8
  • C79.02 Secondary malignant neoplasm of left kidney and renal pelvis from V24 HCC 8
  • C79.31 Secondary malignant neoplasm of brain from V24 HCC 8
  • C79.32 Secondary malignant neoplasm of cerebral meninges from V24 HCC 8
  • C79.40 Secondary malignant neoplasm of unspecified part of nervous system from V24 HCC 8
  • C79.49 Secondary malignant neoplasm of other parts of nervous system from V24 HCC 8
  • C79.70 Secondary malignant neoplasm of unspecified adrenal gland from V24 HCC 8
  • C79.71 Secondary malignant neoplasm of right adrenal gland from V24 HCC 8
  • C79.72 Secondary malignant neoplasm of left adrenal gland from V24 HCC 8
  • C7B.00 Secondary carcinoid tumors, unspecified site from V24 HCC 8
  • C7B.01 Secondary carcinoid tumors of distant lymph nodes from V24 HCC 8
  • C7B.02 Secondary carcinoid tumors of liver from V24 HCC 8
  • C7B.03 Secondary carcinoid tumors of bone from V24 HCC 8
  • C7B.04 Secondary carcinoid tumors of peritoneum from V24 HCC 8
  • C7B.09 Secondary carcinoid tumors of other sites from V24 HCC 8
  • C7B.1 Secondary Merkel cell carcinoma from V24 HCC 8
  • C7B.8 Other secondary neuroendocrine tumors from V24 HCC 8
  • C84.10 Sezary disease, unspecified site from V24 HCC 10
  • C84.11 Sezary disease, lymph nodes of head, face, and neck from V24 HCC 10
  • C84.12 Sezary disease, intrathoracic lymph nodes from V24 HCC 10
  • C84.13 Sezary disease, intra-abdominal lymph nodes from V24 HCC 10
  • C84.14 Sezary disease, lymph nodes of axilla and upper limb from V24 HCC 10
  • C84.15 Sezary disease, lymph nodes of inguinal region and lower limb from V24 HCC 10
  • C84.16 Sezary disease, intrapelvic lymph nodes from V24 HCC 10
  • C84.17 Sezary disease, spleen from V24 HCC 10
  • C84.18 Sezary disease, lymph nodes of multiple sites from V24 HCC 10
  • C84.19 Sezary disease, extranodal and solid organ sites from V24 HCC 10
  • C84.1A Sezary disease, in remission from V24 HCC 10
  • C92.00 Acute myeloblastic leukemia, not having achieved remission from V24 HCC 8
  • C92.01 Acute myeloblastic leukemia, in remission from V24 HCC 8
  • C92.02 Acute myeloblastic leukemia, in relapse from V24 HCC 8
  • C92.30 Myeloid sarcoma, not having achieved remission from V24 HCC 9
  • C92.31 Myeloid sarcoma, in remission from V24 HCC 9
  • C92.32 Myeloid sarcoma, in relapse from V24 HCC 9
  • C92.50 Acute myelomonocytic leukemia, not having achieved remission from V24 HCC 8
  • C92.51 Acute myelomonocytic leukemia, in remission from V24 HCC 8
  • C92.52 Acute myelomonocytic leukemia, in relapse from V24 HCC 8
  • C92.60 Acute myeloid leukemia with 11q23-abnormality not having achieved remission from V24 HCC 8
  • C92.61 Acute myeloid leukemia with 11q23-abnormality in remission from V24 HCC 8
  • C92.62 Acute myeloid leukemia with 11q23-abnormality in relapse from V24 HCC 8
  • C92.A0 Acute myeloid leukemia with multilineage dysplasia, not having achieved remission from V24 HCC 8
  • C92.A1 Acute myeloid leukemia with multilineage dysplasia, in remission from V24 HCC 8
  • C92.A2 Acute myeloid leukemia with multilineage dysplasia, in relapse from V24 HCC 8
  • C93.00 Acute monoblastic/monocytic leukemia, not having achieved remission from V24 HCC 8
  • C93.01 Acute monoblastic/monocytic leukemia, in remission from V24 HCC 8
  • C93.02 Acute monoblastic/monocytic leukemia, in relapse from V24 HCC 8
  • C94.00 Acute erythroid leukemia, not having achieved remission from V24 HCC 8
  • C94.01 Acute erythroid leukemia, in remission from V24 HCC 8
  • C94.02 Acute erythroid leukemia, in relapse from V24 HCC 8
  • C94.20 Acute megakaryoblastic leukemia not having achieved remission from V24 HCC 8
  • C94.21 Acute megakaryoblastic leukemia, in remission from V24 HCC 8
  • C94.22 Acute megakaryoblastic leukemia, in relapse from V24 HCC 8
  • C94.40 Acute panmyelosis with myelofibrosis not having achieved remission from V24 HCC 8
  • C94.41 Acute panmyelosis with myelofibrosis, in remission from V24 HCC 8
  • C94.42 Acute panmyelosis with myelofibrosis, in relapse from V24 HCC 8
  • D46.22 Refractory anemia with excess of blasts 2 from V24 HCC 46
  • E34.00 Carcinoid syndrome, unspecified from V24 HCC 12
  • E34.01 Carcinoid heart syndrome from V24 HCC 12
  • E34.09 Other carcinoid syndrome from V24 HCC 12
  • I31.31 Malignant pericardial effusion in diseases classified elsewhere new to V28
  • J91.0 Malignant pleural effusion new to V28
  • R18.0 Malignant ascites new to V28

Every code above carries the full HCC 17 weight when documented and reported on a Medicare Advantage encounter. The code link opens its full page with the complete risk adjustment card.

Questions About HCC 17

What is HCC 17 in the CMS-HCC model?

HCC 17 is CMS-HCC Category 17 (Cancer Metastatic to Lung, Liver, Brain, and Other Organs; Acute Myeloid Leukemia Except Promyelocytic) in the V28 risk adjustment model. It covers 78 ICD-10-CM diagnosis codes that raise a Medicare Advantage beneficiary's risk score when documented.

What is the RAF weight for HCC 17?

For payment year 2026, HCC 17 adds 4.209 to the RAF score of a community, non-dual, aged beneficiary. The published weights range from 1.952 to 4.235 across the seven payment segments shown above.

Related References

All HCC CategoriesHCC 18 CodesHCC 19 CodesHCC 20 CodesHCC 21 CodesHCC 22 CodesHCC 23 CodesV24 to V28: What ChangedICD-10-CM Code Lookup

Source: Centers for Medicare & Medicaid Services, Payment Year 2026 risk adjustment mapping and model software releases (CMS-HCC V28), applied to the FY 2026 ICD-10-CM code set. ICD List is not affiliated with CMS.